Vol 91, No 2 (2020)
Research paper
Published online: 2020-02-28

open access

Page views 2152
Article views/downloads 917
Get Citation

Connect on Social Media

Connect on Social Media

The effect of lymph node metastasis on overall survival and disease-free survival in vulvar cancer patients

Volkan Karataşlı1, Selçuk Erkılınç1, İlker Çakır1, Behzat Can1, Tuğba Karadeniz2, Mehmet Gökçü1, Muzaffer Sancı1
Pubmed: 32141050
Ginekol Pol 2020;91(2):62-67.


Objectives: To examine the effect of lymphadenectomy on survival in patients with squamous cell vulvar carcinoma.
Material and methods: Patients with squamous cell vulvar cancer who underwent surgery were retrospectively analyzed.
All procedures were performed according to current recommendations/standard of treatment. The clinical and pathological
features were examined. Sixty-eight patients were studied. The mean age was 64.7 ± 10.9 years. Twenty-three (33.8%)
patients had nodal metastasis. Most patients (60.3%) were in stage IB. Adjuvant radiotherapy and chemo-radiotherapy were
administered to 33.8% and 25% of the patients, respectively. The median follow-up time was 28.5 (4–183) months. Recurrence
occurred in 18 (26.5%) cases.
Results: There was no significant difference between node-positive and node-negative patients in terms of age, number of
dissected lymph nodes and recurrence. Tumor diameter was significantly higher in the metastatic group. Age and surgical
margin positivity were independent prognostic factors for overall survival (OS). Surgical margin positivity and lymph node
metastasis had no effect on disease-free survival (DFS).
Conclusions: Our results showed that age and surgical margin positivity were independent prognostic factors for OS.
Although surgical margin positivity increased the risk of recurrence in univariate analysis, it was not a significant factor
affecting DFS. OS was significantly lower in patients with lymph node metastasis.

Article available in PDF format

View PDF Download PDF file


  1. Banas T, Pitynski K, Jach R, et al. Primary Vulvo-Vaginal Cancers: Trends in Incidence and Mortality in Poland (1999-2012). Gynecol Obstet Invest. 2015; 80(4): 240–245.
  2. Rogers LJ, Cuello MA. Cancer of the vulva. Int J Gynaecol Obstet. 2018; 143 Suppl 2: 4–13.
  3. Oonk MHM, Planchamp F, Baldwin P, et al. European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer. Int J Gynecol Cancer. 2017; 27(4): 832–837.
  4. Koh WJ, Greer BE, Abu-Rustum NR, et al. Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017; 15(1): 92–120.
  5. Mahner S, Jueckstock J, Hilpert F, et al. AGO-CaRE 1 investigators. Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. J Natl Cancer Inst. 2015; 107(3).
  6. Sznurkowski JJ, Milczek T, Emerich J. Prognostic factors and a value of 2009 FIGO staging system in vulvar cancer. Arch Gynecol Obstet. 2013; 287(6): 1211–1218.
  7. van der Steen S, de Nieuwenhof HP, Massuger L, et al. New FIGO staging system of vulvar cancer indeed provides a better reflection of prognosis. Gynecol Oncol. 2010; 119(3): 520–525.
  8. Zhou J, Shan G. The prognostic role of FIGO stage in patients with vulvar cancer: a systematic review and meta-analysis. Curr Med Res Opin. 2016; 32(6): 1121–1130.
  9. Sznurkowski JJ, Emerich J. Characteristic features of recurrences of squamous cell carcinoma of the vulva. Ginekol Pol. 2010; 81(1): 12–19.
  10. Heaps JM, Fu YS, Montz FJ, et al. Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol. 1990; 38(3): 309–314.
  11. Nooij LS, van der Slot MA, Dekkers OM, et al. Tumour-free margins in vulvar squamous cell carcinoma: Does distance really matter? Eur J Cancer. 2016; 65: 139–149.
  12. Te Grootenhuis NC, van der Zee AGJ, van Doorn HC, et al. Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I. Gynecol Oncol. 2016; 140(1): 8–14.
  13. Gadducci A, Ferrero A, Tana R, et al. Prognostic value of lymph node status and number of removed nodes in patients with squamous cell carcinoma of the vulva treated with modified radical vulvectomy and inguinal-femoral lymphadenectomy. Eur J Gynaecol Oncol. 2012; 33(6): 640–643.
  14. Te Grootenhuis NC, Pouwer AFW, de Bock GH, et al. Prognostic factors for local recurrence of squamous cell carcinoma of the vulva: A systematic review. Gynecol Oncol. 2018; 148(3): 622–631.
  15. Woelber L, Griebel LF, Eulenburg C, et al. Role of tumour-free margin distance for loco-regional control in vulvar cancer-a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study. Eur J Cancer. 2016; 69: 180–188.
  16. Hacker NF. Revised FIGO staging for carcinoma of the vulva. Int J Gynaecol Obstet. 2009; 105(2): 105–106.
  17. Woelber L, Eulenburg C, Choschzick M, et al. Prognostic role of lymph node metastases in vulvar cancer and implications for adjuvant treatment. Int J Gynecol Cancer. 2012; 22(3): 503–508.
  18. Cheng Xi, Zang R, Wu X, et al. Recurrence patterns and prognostic factors in Chinese patients with squamous cell carcinoma of the vulva treated with primary surgery. Int J Gynecol Cancer. 2009; 19(1): 158–162.
  19. Nicoletto MO, Parenti A, Del Bianco P, et al. Vulvar cancer: prognostic factors. Anticancer Res. 2010; 30(6): 2311–2317.
  20. Akhtar-Danesh N, Elit L, Lytwyn A, et al. Trends in incidence and survival of women with invasive vulvar cancer in the United States and Canada: a population-based study. Gynecol Oncol. 2014; 134(2): 314–318.
  21. Barlow EL, Kang YJ, Hacker NF, et al. Changing Trends in Vulvar Cancer Incidence and Mortality Rates in Australia Since 1982. Int J Gynecol Cancer. 2015; 25(9): 1683–1689.
  22. Kang YJ, Smith M, Barlow E, et al. Vulvar cancer in high-income countries: Increasing burden of disease. Int J Cancer. 2017; 141(11): 2174–2186.
  23. Maggino T, Landoni F, Sartori E, et al. Patterns of recurrence in patients with squamous cell carcinoma of the vulva. A multicenter CTF Study. Cancer. 2000; 89(1): 116–122.
  24. Meelapkij P, Suprasert P, Baisai O. Treatment Outcomes of Patients with Squamous Cell Carcinoma of the Vulva: The Largest Series from a Tertiary Care Hospital. Obstet Gynecol Int. 2018; 2018: 4723167.
  25. Raspagliesi F, Hanozet F, Ditto A, et al. Clinical and pathological prognostic factors in squamous cell carcinoma of the vulva. Gynecol Oncol. 2006; 102(2): 333–337.
  26. Gadducci A, Cionini L, Romanini A, et al. Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol. 2006; 60(3): 227–241.
  27. Panici PB, Tomao F, Domenici L, et al. Prognostic role of inguinal lymphadenectomy in vulvar squamous carcinoma: younger and older patients should be equally treated. A prospective study and literature review. Gynecol Oncol. 2015; 137(3): 373–379.
  28. Yap J, O'Neill D, Nagenthiran S, et al. Current insights into the aetiology, pathobiology, and management of local disease recurrence in squamous cell carcinoma of the vulva. BJOG. 2017; 124(6): 946–954.